From patient-derived tumor organoids to personalized cancer therapy: advancing treatment for advanced solid tumors - Takeaways - MDSpire

Utilizing Patient-Derived Tumor Organoids for Tailored Cancer Treatment: Progress in Managing Advanced Solid Tumors

  • By

  • Gang Wang

  • Zhibin Tan

  • Wenting Jia

  • Yuanyuan Liu

  • Huan Wang

  • Wenbo Sun

  • Weiwei Sun

  • Lu Meng

  • Yudong Zhang

  • Ning Liu

  • Feng Li

  • Hongchao Dong

  • July 20, 2026

Share

  • 1

    Patient-derived tumor organoids (PDTOs) have a 91.5% success rate in establishing organoids from advanced solid tumors.

  • 2

    PDTOs partially recapitulate the histopathological features and proliferative activity of matched original tumors.

  • 3

    PDTO-based drug sensitivity testing shows 85.0% accuracy in predicting clinical treatment outcomes for advanced solid tumors.

  • 4

    The study highlights PDTOs' potential in overcoming multidrug resistance in patients with advanced solid tumors.

  • 5

    Future large-scale studies are needed to further validate the clinical translational value of PDTOs in individualized cancer treatment.

Original Source(s)

From patient-derived tumor organoids to personalized cancer therapy: advancing treatment for advanced solid tumors

  • by Gang Wang, Zhibin Tan, Wenting Jia, Yuanyuan Liu, Huan Wang, Wenbo Sun, Weiwei Sun, Lu Meng, Yudong Zhang, Ning Liu, Feng Li, Hongchao Dong

  • July 20, 2026

Related Content

Global research landscape and hotspots of paraptosis: a multi-database bibliometric analysis with a focused literature review

The Secrets of the Gut

Going beyond the gut: why microbiome testing is the next big thing in drug development

Durable response to ALK inhibition in low-allele-frequency SPTBN1–ALK–rearranged gastric cancer followed by lineage plasticity–mediated resistance: a case report